- Article
- Source: Campus Sanofi
- 23 Oct 2023
Therapeutic indications for Praluent® (alirocumab)
![](https://pro.campus.sanofi/.imaging/mte/portal/3840/dam/Portal/UK/Articles/tratamiento-hipolipemiante-hero-1.jpg/jcr:content/tratamiento-hipolipemiante-hero%201.jpg)
![Praluent logo](https://pro.campus.sanofi/.imaging/mte/portal/3840/dam/Portal/UK/Articles/Dyslipidaemia/specific-characteristics/Image/praluent_registered_4c_left_triangle_notag.2022-09-09-18-24-23.png/jcr:content/praluent_registered_4c_left_triangle_notag.2022-09-09-18-24-23.png)
Primary hypercholesterolaemia and mixed dyslipidaemia1
- PRALUENT® is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:
- in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or
- alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant or for whom a statin is contraindicated
Established atherosclerotic cardiovascular disease1
-
PRALUENT® is indicated in adults with established atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering LDL-C levels as an adjunct to correction of other risk factors:
-
in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies, or
-
alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant or for whom a statin is contraindicated
-
Praluent®
Find more information on Indication, Administration and Mechanism of Action and watch videos about Praluent®.
![](https://pro.campus.sanofi/.imaging/mte/portal/3840/dam/Portal/UK/Articles/Dyslipidaemia/unmet-needs/Image/Group-44.jpg/jcr:content/Group%2044.jpg)
![](https://pro.campus.sanofi/.imaging/mte/portal/3840/dam/Portal/UK/Articles/Diabetes/Image/MicrosoftTeams-image--2-.jpg/jcr:content/MicrosoftTeams-image%20(2).jpg)
References
- Praluent Summary of Product Characteristics. Available at https://www.medicines.org.uk/emc/product/8093/smpc. Accessed October 2023.
MAT-XU-2204608 (v3.0) Date of Preparation: October 2023